Abstract

On November 7th and 8th, 2022, The National Institute of Allergy and Infectious Diseases (NIAID), part of the National Institutes of Health (NIH), The Coalition for Epidemic Preparedness Innovation (CEPI), The Bill & Melinda Gates Foundation (BMGF), The Biomedical Advanced Research and Development Authority (BARDA), and the Wellcome Trust hosted a virtual workshop entitled “Mucosal Vaccines for SARS-CoV-2: Scientific Gaps and Opportunities.” During the workshop, researchers and vaccine developers from around the world discussed the potential of mucosal vaccines to block SARS-CoV-2 transmission and reviewed the status of SARS-CoV-2 mucosal vaccine research. Here, we summarize key challenges and opportunities in basic, translational, and clinical research that were highlighted during the meeting. We also provide recommendations to advance the field and accelerate the development of mucosal vaccines for SARS-CoV-2.

Details

Title
Mucosal vaccines for SARS-CoV-2: scientific gaps and opportunities—workshop report
Author
Knisely, Jane M. 1   VIAFID ORCID Logo  ; Buyon, Lucas E. 2 ; Mandt, Rebecca 2   VIAFID ORCID Logo  ; Farkas, Rebecca 3 ; Balasingam, Shobana 4 ; Bok, Karin 5 ; Buchholz, Ursula J. 6   VIAFID ORCID Logo  ; D’Souza, M. Patricia 7 ; Gordon, Jennifer L. 8 ; King, Deborah F. L. 4 ; Le, Tung T. 3 ; Leitner, Wolfgang W. 9   VIAFID ORCID Logo  ; Seder, Robert A. 5   VIAFID ORCID Logo  ; Togias, Alkis 9 ; Tollefsen, Stig 3   VIAFID ORCID Logo  ; Vaughn, David W. 10   VIAFID ORCID Logo  ; Wolfe, Daniel N. 11 ; Taylor, Kimberly L. 8 ; Fauci, Anthony S. 12 

1  National Institute of Allergy and Infectious Diseases, National Institutes of Health, Office of the Director, Bethesda, USA (GRID:grid.419681.3) (ISNI:0000 0001 2164 9667); National Institute of Allergy and Infectious Diseases, National Institutes of Health, Division of Microbiology and Infectious Diseases, Bethesda, USA (GRID:grid.419681.3) (ISNI:0000 0001 2164 9667) 
2  National Institute of Allergy and Infectious Diseases, National Institutes of Health, Office of Scientific Management and Operations, Bethesda, USA (GRID:grid.419681.3) (ISNI:0000 0001 2164 9667) 
3  Coalition for Epidemic Preparedness Innovations, Skøyen Atrium, Oslo, Norway (GRID:grid.507196.c) (ISNI:0000 0004 9225 0356) 
4  Wellcome Trust, UK, Infectious Disease, Prevention, London, UK (GRID:grid.52788.30) (ISNI:0000 0004 0427 7672) 
5  National Institutes of Health, Vaccine Research Center, National Institute of Allergy and Infectious Diseases, Bethesda, USA (GRID:grid.94365.3d) (ISNI:0000 0001 2297 5165) 
6  National Institute of Allergy and Infectious Diseases, National Institutes of Health, RNA Viruses Section, Laboratory of Infectious Diseases, Bethesda, US (GRID:grid.419681.3) (ISNI:0000 0001 2164 9667) 
7  National Institutes of Health, Division of AIDS, National Institute of Allergy and Infectious Diseases, Rockville, USA (GRID:grid.94365.3d) (ISNI:0000 0001 2297 5165) 
8  National Institute of Allergy and Infectious Diseases, National Institutes of Health, Division of Microbiology and Infectious Diseases, Bethesda, USA (GRID:grid.419681.3) (ISNI:0000 0001 2164 9667) 
9  National Institute of Allergy and Infectious Diseases, Division of Allergy, Immunology, and Transplantation, Rockville, USA (GRID:grid.419681.3) (ISNI:0000 0001 2164 9667) 
10  Bill & Melinda Gates Foundation, Seattle, USA (GRID:grid.418309.7) (ISNI:0000 0000 8990 8592) 
11  Biomedical Advanced Research and Development Authority, Administration for Strategic Preparedness and Response, Washington, USA (GRID:grid.476870.a) 
12  National Institute of Allergy and Infectious Diseases, National Institutes of Health, Office of the Director, Bethesda, USA (GRID:grid.419681.3) (ISNI:0000 0001 2164 9667) 
Pages
53
Publication year
2023
Publication date
2023
Publisher
Nature Publishing Group
e-ISSN
20590105
Source type
Scholarly Journal
Language of publication
English
DOI
https://doi.org/10.1038/s41541-023-00654-6
ProQuest document ID
2799928206
Copyright
© This is a U.S. Government work and not under copyright protection in the US; foreign copyright protection may apply 2023. This work is published under http://creativecommons.org/licenses/by/4.0/ (the “License”). Notwithstanding the ProQuest Terms and Conditions, you may use this content in accordance with the terms of the License.